46 F.4th 22
1st Cir.2022Background
- CVS Health acquired Omnicare (a long-term care pharmacy provider) in 2015 and allocated about $8.6 billion of goodwill to that acquisition.
- Between 2016–2019 CVS recorded successive goodwill impairments for the Omnicare/LTC reporting unit, ultimately reducing goodwill to about $431 million after more than $8 billion of write-offs.
- Two institutional investors sued, alleging CVS (and certain officers) made false or misleading statements and omissions about the LTC business (customer retention, "synergies," and understanding of customers) during 2016–2018, concealing that customers were fleeing and causing delayed write-downs.
- Plaintiffs relied largely on confidential witnesses who reported customer losses and operational changes after the acquisition.
- The district court dismissed the amended complaint with prejudice for failure to plead any materially false or misleading statement under §10(b)/Rule 10b-5; a Rule 59(e) motion to reconsider (and seek leave to amend) was denied.
- The First Circuit affirmed, holding plaintiffs failed to plead falsity or a duty to disclose with the required particularity and did not justify reconsideration or late amendment.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether complaint alleges a material misrepresentation or omission under §10(b)/Rule 10b-5 | Plaintiffs: public statements (SEC filings, CEO/CFO remarks) painted LTC as healthy/leader and omitted that customer losses were ongoing and material, so statements were misleading | CVS: statements were not false or misleading when made; risks and write-downs were disclosed; plaintiffs plead only hindsight quarrels with business judgment | Held: Dismissed — plaintiffs failed to plead falsity or misleading omissions with particularity; disclosures and subsequent write-downs are consistent with contemporaneous statements |
| Whether plaintiffs impermissibly plead "fraud by hindsight" | Plaintiffs: later impairments show the truth hidden earlier; CWs show customer flight began earlier | CVS: plaintiffs rely on hindsight and anecdote; no specific contemporaneous facts contradicting statements | Held: Dismissed — allegations amount to hindsight; plaintiffs did not show statements false when made |
| Whether boilerplate risk disclosures created a duty to disclose more ("Grand Canyon" theory) | Plaintiffs: risk-factor warnings understated an already-material problem; loss of goodwill was a near-certainty requiring fuller disclosure | CVS: risk warnings were appropriate and not transformed into a duty to disclose absent showing the risk had already materially and unmistakably materialized | Held: Dismissed — plaintiffs did not plead that the warned risk had a near-certainty or had already materialized at the relevant times |
| Whether district court abused discretion in denying leave to amend / reconsideration under Rule 59(e) | Plaintiffs: newly discovered CWs and additional facts justified reconsideration and a proposed second amended complaint | CVS: new evidence was discoverable earlier; plaintiffs waited and failed to properly move for leave to amend before dismissal | Held: Affirmed — denial was not an abuse of discretion; plaintiffs could have sought leave earlier and did not show evidence was unavailable with due diligence |
Key Cases Cited
- Gross v. Summa Four, Inc., 93 F.3d 987 (1st Cir. 1996) (statements must be false when made; no fraud by hindsight)
- Karth v. Keryx Biopharms., Inc., 6 F.4th 123 (1st Cir. 2021) (limits on duty to disclose hypothetical risks; "Grand Canyon" analogy)
- Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (2011) (omission liability only when disclosure is necessary to prevent statements from being misleading)
- ACA Fin. Guar. Corp. v. Advest, Inc., 512 F.3d 46 (1st Cir. 2008) (rejecting fraud-by-hindsight claims based on later disclosures)
- In re Cabletron Sys., Inc., 311 F.3d 11 (1st Cir. 2002) (later disclosures do not retroactively make earlier statements false)
- Suna v. Bailey Corp., 107 F.3d 64 (1st Cir. 1997) (plaintiff must plead that public statements were false or misleading when made)
- In re Biogen Inc. Sec. Litig., 857 F.3d 34 (1st Cir. 2017) (standard for newly discovered evidence to support reconsideration)
- SEC v. Johnston, 986 F.3d 63 (1st Cir. 2021) (half-truths and omissions can be misleading but must be materially inaccurate at the time made)
- Ponsa-Rabell v. Santander Sec. LLC, 35 F.4th 26 (1st Cir. 2022) (materiality and the market's awareness of disclosed information)